Cargando…

Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy

BACKGROUND: T cells engineered to target CD19 antigen on neoplastic B cells represent the most striking example of CAR-T cell therapy. The success rate of this therapy is affected by several limitations: target antigen loss, and/or acquisition of a senescent/exhausted phenotype by CAR and non-CAR T...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Matteis, Serena, Casadei, Beatrice, Lolli, Ginevra, Dicataldo, Michele, Barbato, Francesco, Dan, Elisa, Paccagnella, Andrea, Sinigaglia, Barbara, Bertuzzi, Clara, Arcari, Annalisa, Zazzeroni, Luca, Bernuzzi, Patrizia, Laprovitera, Noemi, Storci, Gianluca, Bertuccio, Salvatore Nicola, Ferracin, Manuela, Bonafè, Massimiliano, Zinzani, Pier Luigi, Bonifazi, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584643/ https://www.ncbi.nlm.nih.gov/pubmed/36275688 http://dx.doi.org/10.3389/fimmu.2022.994731

Ejemplares similares

Peripheral blood cellular profile at pre-lymphodepletion is associated with CD19-targeted CAR-T cell-associated neurotoxicity
por: De Matteis, Serena, et al.
Publicado: (2023)

Pre-transplant CD69+ extracellular vesicles are negatively correlated with active ATLG serum levels and associate with the onset of GVHD in allogeneic HSCT patients
por: Storci, Gianluca, et al.
Publicado: (2023)

Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review
por: Pensato, Umberto, et al.
Publicado: (2022)

Correction to: Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review
por: Pensato, Umberto, et al.
Publicado: (2022)

The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia
por: Maffini, Enrico, et al.
Publicado: (2022)

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience
por: Casadei, Beatrice, et al.
Publicado: (2021)

The role of extracellular DNA in COVID-19: Clues from inflamm-aging
por: Storci, Gianluca, et al.
Publicado: (2021)

Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity
por: Pensato, Umberto, et al.
Publicado: (2021)

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient
por: Lolli, Ginevra, et al.
Publicado: (2020)

Turn to TCRs when CARs fail
por: Stauss, Hans J.
Publicado: (2017)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR
por: Laprovitera, Noemi, et al.
Publicado: (2018)

Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study
por: Bonifazi, Francesca, et al.
Publicado: (2018)

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study
por: Liu, Chun, et al.
Publicado: (2023)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

The p53 codon 72 proline allele is endowed with enhanced cell-death inducing potential in cancer cells exposed to hypoxia
por: Sansone, P, et al.
Publicado: (2007)

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma
por: Casadei, Beatrice, et al.
Publicado: (2020)

Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients
por: Casadei, Beatrice, et al.
Publicado: (2020)

Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes
por: Bonafè, Massimiliano, et al.
Publicado: (2020)

Cancer of Unknown Primary: Challenges and Progress in Clinical Management
por: Laprovitera, Noemi, et al.
Publicado: (2021)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
por: Rose, Peter G., et al.
Publicado: (2023)

Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella
por: Prattichizzo, Francesco, et al.
Publicado: (2021)

CAR-T cell therapy: a potential new strategy against prostate cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus
por: Del Coco, Laura, et al.
Publicado: (2019)

Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients
por: Sabbatinelli, Jacopo, et al.
Publicado: (2021)

Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells
por: D'Anello, Laura, et al.
Publicado: (2010)

Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities
por: De Matteis, Serena, et al.
Publicado: (2018)

Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti‐CD19 CAR‐T therapy: a case report
por: Mackenzie, Strachan, et al.
Publicado: (2021)

Convergent adaptation of cellular machineries in the evolution of large body masses and long life spans
por: Croco, Eleonora, et al.
Publicado: (2017)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Age-related M1/M2 phenotype changes in circulating monocytes from healthy/unhealthy individuals
por: Costantini, Andrea, et al.
Publicado: (2018)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Short Interfering RNA Directed against the SLUG Gene Increases Cell Death Induction in Human Melanoma Cell Lines Exposed to Cisplatin and Fotemustine
por: Vannini, Ivan, et al.
Publicado: (2007)

Brain dysfunction in COVID‐19 and CAR‐T therapy: cytokine storm‐associated encephalopathy
por: Pensato, Umberto, et al.
Publicado: (2021)

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy
por: Schepisi, Giuseppe, et al.
Publicado: (2021)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o8t7dcvdg72orm46r7op77k4id